 safeti effect plu zidovudin asymptomat individu human immunodefici viru safeti continu i.v conjunct zidovudin zdv asymptomat patient human immunodefici viru clinic immunolog viral paramet phase i/ii trial dose escal crossov arm daili dose presenc zdv increas antigenemia signific transient increas cell infus dose natur lymphokine-activ killer activ dose hypodens eosinophil solubl receptor patient avail long-term month baselin month count baselin mean increas patient signific patient neg serum start therapi none antigenem long-term follow-up